Discovery of BIIB042, a potent, selective, and orally bioavailable γ-secretase modulator

ACS Medicinal Chemistry Letters

Volumn 2, Issue 10, 2011, Pages 786-791

  Peng, Hairuo ^a   Talreja, Tina ^a   Xin, Zhili ^a   Cuervo, J Hernan ^a   Kumaravel, Gnanasambandam ^a   Humora, Michael J ^a   Xu, Lin ^a   Rohde, Ellen ^a   Gan, Lawrence ^a   Jung, Mi Young ^a   Shackett, Melanie N ^a   Chollate, Sowmya ^a   Dunah, Anthone W ^a   Snodgrass Belt, Pamela A ^a   Arnold, H Moore ^a   Taveras, Arthur G ^a   Rhodes, Kenneth J ^a   Scannevin, Robert H ^a  

^a BIOGEN   (United States)

Author keywords

Alzheimer's; amyloid; GSM; Mannich reaction; Secretase

Indexed keywords

BIIB 042; CARBOXYLIC ACID DERIVATIVE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GAMMA SECRETASE; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CELL ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EXPOSURE; DRUG PENETRATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

MACACA FASCICULARIS; MUS; RATTUS;

EID: 80054749437     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml200175q     Document Type: Article

References (16)

1. Citron, M. Alzheimer's disease: Strategies for disease modification Nature Rev. Drug Discovery 2010, 9, 387-398
2. Hardy, J.; Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics Science 2002, 297, 353-356 (Pubitemid 34790756)
3. Tanzi, R. E.; Bertram, L. Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective Cell 2005, 120, 545-555 (Pubitemid 40269768)
4. Walsh, D. M.; Selkoe, D. J. Deciphering the molecular basis of memory failure in Alzheimer's disease Neuron 2004, 44, 181-193 (Pubitemid 39348839)
5. De Strooper, B.; Vassar, R.; Golde, T. The secretases: Enzymes with therapeutic potential in Alzheimer disease Nat. Rev. Neurol. 2010, 6, 99-107
6. Jarrett, J. T.; Berger, E. P.; Lansbury, P. T., Jr. The carboxy terminus of β amyloid protein is critical for the seeding of amyloid formation: Implications for pathogenesis of Alzheimer's disease Biochemistry 1993, 32, 4693-4697 (Pubitemid 23162022)
7. McGowan, E.; Pickford, F.; Kim, J.; Onstead, L.; Eriksen, J.; Yu, C.; Skipper, L.; Murphy, M. P.; Beard, J.; Das, P.; Jansen, K.; DeLucia, M.; Lin, W.-L.; Dolios, G.; Wang, R.; Eckman, C. B.; Dickson, D. W.; Hutton, M.; Hardy, J.; Golde, T. Aβ42 is essential for parenchymal and vascular amyloid deposition in mice Neuron 2005, 47, 191-199 (Pubitemid 41019251)
8. Shankar, G. M.; Li, S.; Mehta, T. H.; Garcia-Munoz, A.; Shepardson, N. E.; Smith, I.; Brett, F. M.; Farrell, M. A.; Rowan, M. J.; Lemere, C. A.; Regan, C. M.; Walsh, D. M.; Sabatini, B. L.; Selkoe, D. J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory Nat. Med. 2008, 14, 837-842
9. Wong, G. T.; Manfra, D.; Poulet, F. M.; Zhang, Q.; Josien, H.; Bara, T.; Engstrom, L.; Pinzon-Ortiz, M.; Fine, J. S.; Lee, H.-J. J.; Zhang, L.; Higgins, G. A.; Parker, E. M. Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation J. Biol. Chem. 2004, 279, 12876-12882 (Pubitemid 38445862)
10. Milano, J.; McKay, J.; Dagenais, C.; Foster-Brown, L.; Pognan, F.; Gadient, R.; Jacobs, R. T.; Zacco, A.; Greenberg, B.; Ciaccio, P. J. Modulation of Notch processing by γ-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation Toxicol. Sci. 2004, 82, 341-358 (Pubitemid 39485346)
11. Weggen, S.; Eriksen, J. L.; Das, P.; Sagi, S. A.; Wang, R.; Pietrizik, C. U.; Findlay, K. A.; Smith, T. E.; Murphy, M. P.; Bulter, T.; Kang, D. E.; Marquez-sterling, N.; Golde, T. E.; Koo, E. H. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity Nature 2001, 414, 212-216 (Pubitemid 33051236)
12. Eriksen, J. L.; Sagi, S. A.; Smith, T. E.; Weggen, S.; Das, P.; McLendon, D. C.; Ozols, V. V.; Jessing, K. W.; Zavitz, K. H.; Koo, E. H.; Golde, T. E. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo J. Clin. Invest. 2004, 112, 440-449 (Pubitemid 38063773)
13. Imbimbo, B. P.; Hutter-Paier, B.; Villetti, G.; Facchinetti, F.; Cenacchi, V.; Volta, R.; Lanzillotta, A.; Pizzi, M.; Windisch, M. CHF5074, a novel γ-secretase modulator, attenuates brain β-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease Br. J. Pharmacol. 2009, 156, 982-993
14. Stanton, M. G.; Hubbs, J.; Sloman, D.; Hamblett, C.; Andrade, P.; Angagaw, M.; Bi, G.; Black, R. M.; Crispino, J.; Cruz, J. C.; Fan, E.; Farris, G.; Hughes, B. L.; Kenific, C. M.; Middleton, R. E.; Nikov, G.; Sajonz, P.; Shah, S.; Shomer, N.; Szewczak, A. A.; Tanga, F.; Tudge, M. T.; Shearman, M.; Munoz, B. Fluorinated piperidine acetic acids as γ-secretase modulators Bioorg. Med. Chem. Lett. 2010, 20, 755-758
15. Oehlrich, D.; Berthelot, D. J.-C.; Gijsen, H. γ-Secretase modulators as potential disease modifying Anti-Alzheimer's drugs J. Med. Chem. 2011, 54, 669-698
16. Jarriault, S.; Le Bail, O.; Hirsinger, E.; Pourquié, O.; Logeat, F.; Strong, C. F.; Brou, C.; Seidah, N. G.; Isra, I. A. Delta-1 activation of notch-1 signaling results in HES-1 transactivation Mol. Cell. Biol. 1998, 18, 7423-7431 (Pubitemid 28533061)